Adiponectin is an antiatherogenic agent, meaning it helps prevent the development of atheroschlerotic plaque in blood vessels and slows the progression of atherosclerosis in coronary vessels. It does this by acting directly upon the vessel wall, inhibiting adhesive molecules from contributing to plaque formation and acts as a blocking agent to the formation of foam cells. In the skeletal muscle and the liver, adiponectin serves to promote insulin sensitivity and a positive blood lipid profile. Visceral adiposity reduces adiponectin concentrations. Lowering the adiponectin concentrations lessens the cardioprotective effect, leading to increased cardiovascular risk.
Leptin regulates energy metabolism and balance in conjunction with the brain’s hypothalamus. Leptin is currently being touted as having cardioprotective benfits among its others roles in metabolism Leptin concentrations adjust in response to obesity and contribute to insulin resistance. The changes in leptin concentration have also been recognized as a risk factor for coronary heart disease. Likewise increased resistin concentrations correlate with obesity related inflammation and may be associated with the initiation and progression of atherosclerotic lesions. Resistin also promotes insulin resistance, although the actual mechanism is not known.